Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soquelitinib in Moderate to Severe Atopic Dermatitis
NCT07441395Phase 2Recruiting
- Sponsor
- Corvus Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soquelitinib in atopic dermatitis (AD), sponsored by Corvus Pharmaceuticals. Started Feb 2026; status: recruiting.
02
Drugs
soquelitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07441395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441395.